Can't find what you're looking for?
View all search resultsCan't find what you're looking for?
View all search resultsA malaria drug taken by US President Donald Trump to prevent COVID-19 did not show any benefit versus placebo in reducing coronavirus infection among healthcare workers, according to clinical trial results published on Wednesday.
The anti-malaria drug touted by US President Donald Trump as a COVID-19 treatment was ineffective for patients with a mild version of the disease in a study conducted by researchers at the University of Minnesota.
The World Health Organization (WHO) said on Saturday that it was discontinuing its trials of the malaria drug hydroxychloroquine and combination HIV drug lopinavir/ritonavir in hospitalized patients with COVID-19 after they failed to reduce mortality.
The US National Institutes of Health said on Saturday it has halted a clinical trial to evaluate the safety and effectiveness of the malaria drug hydroxychloroquine for the treatment of hospitalized COVID-19 patients.
Swiss drugmaker Novartis is halting its trial of malaria drug hydroxychloroquine (HCQ) against COVID-19 after struggling to find participants, it said on Friday, as data emerged from other studies raising doubts about its efficacy.
The World Health Organization said on Wednesday that testing of the malaria drug hydroxychloroquine in its large multi-country trial of treatments for COVID-19 patients had been halted after new data and studies showed no benefit.
The US Food and Drug Administration on Monday revoked its emergency use authorization for hydroxychloroquine to treat COVID-19, but quickly came under fire from President Donald Trump, who said only US agencies have failed to grasp its benefit in fighting the coronavirus.
Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.
Thank you for sharing your thoughts. We appreciate your feedback.